Literature DB >> 31912169

Intrauterine growth restriction induces skin inflammation, increases TSLP and impairs epidermal barrier function.

Laura Polányi1,2, Carien M Niessen3, Christina Vohlen1,2, Julia Stinn3, Tobias Kretschmer2, Vanessa Jentgen1, Dharmesh Hirani4, Silke V Koningsbruggen-Rietschel5, Jörg Dötsch2, Miguel A Alejandre Alcazar6,7,8.   

Abstract

Intrauterine growth restriction (IUGR) and low birth weight are risk factors for childhood asthma. Atopic march describes the progression from early dermatitis to asthma during life. Since inflammatory signaling is linked to increased airway resistance and lung remodeling in rats after IUGR, we queried if these findings are related to skin inflammatory response. Firstly, we induced IUGR in Wistar rats by isocaloric protein restriction during gestation. IUGR rats showed lower body weight at postnatal day 1 (P1), catch-up growth at P21, and similar body weight like controls at P90. At P1 and P90, mRNA of inflammatory as well as fibrotic markers and number of skin immune cells (macrophages) were increased after IUGR. Skin thymic stromal lymphopoietin (TSLP) mRNA at P1 and serum TSLP at P1 and P21 were elevated in IUGR. Moreover, IUGR impaired transepidermal water loss at P21 and P90. IUGR induced higher. Secondly, the increase of TEWL after Oxazolone treatment as a model of atopic dermatitis (AD) was greater in IUGR than in Co. Our data demonstrate an early inflammatory skin response, which is linked to persistent macrophage infiltration in the skin and impaired epidermal barrier function after IUGR. These findings coupled with elevated TSLP could underlie atopic diseases in rats after IUGR. KEY MESSAGES: • The present study shows that IUGR increases macrophage infiltration and induces an inflammatory and fibrotic gene expression pattern in the skin of newborn rats. • Early postnatal inflammatory response in the skin after IUGR is followed by impaired epidermal barrier function later in life. • IUGR aggravates transepidermal water loss in an experimental atopic dermatitis model, possibly through elevated TSLP in skin and serum. • Early anti-inflammatory treatment and targeting TSLP signaling could offer novel avenues for early prevention of atopic disorders and late asthma in high-risk infants.

Entities:  

Keywords:  Asthma; Atopic diseases; Intrauterine growth restriction (IUGR); Skin; TSLP

Mesh:

Substances:

Year:  2020        PMID: 31912169     DOI: 10.1007/s00109-019-01867-w

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  47 in total

1.  TSLP promote M2 macrophages polarization and cardiac healing after myocardial infarction.

Authors:  Debin Liu; Mengqi Guo; Peng Zhou; Jie Xiao; Xiaoping Ji
Journal:  Biochem Biophys Res Commun       Date:  2019-06-19       Impact factor: 3.575

2.  Thymic stromal lymphopoietin amplifies the differentiation of alternatively activated macrophages.

Authors:  Hongwei Han; Mark B Headley; Whitney Xu; Michael R Comeau; Baohua Zhou; Steven F Ziegler
Journal:  J Immunol       Date:  2012-12-28       Impact factor: 5.422

3.  Thymic Stromal Lymphopoietin Signaling Pathway Inhibition Attenuates Airway Inflammation and Remodeling in Rats with Asthma.

Authors:  Zhe Cheng; Xi Wang; Ling-Ling Dai; Liu-Qun Jia; Xiao-Gang Jing; Ying Liu; Huan Wang; Peng-Fei Li; Lin An; Meng Liu
Journal:  Cell Physiol Biochem       Date:  2018-06-21

Review 4.  The importance of TSLP in allergic disease and its role as a potential therapeutic target.

Authors:  Antonella Cianferoni; Jonathan Spergel
Journal:  Expert Rev Clin Immunol       Date:  2014-11       Impact factor: 4.473

5.  Study of the stratum corneum barrier function by transepidermal water loss measurements: comparison between two commercial instruments: Evaporimeter and Tewameter.

Authors:  A O Barel; P Clarys
Journal:  Skin Pharmacol       Date:  1995

Review 6.  Epidermal barrier dysfunction in atopic dermatitis.

Authors:  Michael J Cork; Simon G Danby; Yiannis Vasilopoulos; Jonathan Hadgraft; Majella E Lane; Manar Moustafa; Richard H Guy; Alice L Macgowan; Rachid Tazi-Ahnini; Simon J Ward
Journal:  J Invest Dermatol       Date:  2009-06-04       Impact factor: 8.551

7.  Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease.

Authors:  Sun Ying; Brian O'Connor; Jonathan Ratoff; Qiu Meng; Cailong Fang; David Cousins; Guizhen Zhang; Shuyan Gu; Zhongli Gao; Betty Shamji; Matthew J Edwards; Tak H Lee; Chris J Corrigan
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

8.  Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

Authors:  Vassili Soumelis; Pedro A Reche; Holger Kanzler; Wei Yuan; Gina Edward; Bernhart Homey; Michel Gilliet; Steve Ho; Svetlana Antonenko; Annti Lauerma; Kathleen Smith; Daniel Gorman; Sandra Zurawski; Jon Abrams; Satish Menon; Terri McClanahan; Rene de Waal-Malefyt Rd; Fernando Bazan; Robert A Kastelein; Yong-Jun Liu
Journal:  Nat Immunol       Date:  2002-06-10       Impact factor: 25.606

9.  Thymic stromal lymphopoietin contribution to the recruitment of circulating fibrocytes to the lung in a mouse model of chronic allergic asthma.

Authors:  Zhuang-Gui Chen; Ping Meng; Hong-Tao Li; Ming Li; Li-Fen Yang; Yan Yan; Ya-Ting Li; Xiao-Ling Zou; De-Yun Wang; Tian-Tuo Zhang
Journal:  J Asthma       Date:  2017-10-30       Impact factor: 2.515

10.  Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.

Authors:  Shadmehr Demehri; Mitsuru Morimoto; Michael J Holtzman; Raphael Kopan
Journal:  PLoS Biol       Date:  2009-05-19       Impact factor: 8.029

View more
  1 in total

1.  The Acute Hepatic NF-κB-Mediated Proinflammatory Response to Endotoxemia Is Attenuated in Intrauterine Growth-Restricted Newborn Mice.

Authors:  Miguel A Zarate; Robyn K De Dios; Durganili Balasubramaniyan; Lijun Zheng; Laura G Sherlock; Paul J Rozance; Clyde J Wright
Journal:  Front Immunol       Date:  2021-09-01       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.